Exagen Inc. filed a Form S-3 registration statement with the SEC on November 10, 2026, covering up to $150.0 million in securities and including a sales agreement prospectus supplement for up to $50.0 million in common stock through TD Securities (USA) LLC.

Key Highlights

  • Shelf offering size: The base prospectus covers up to $150.0 million in the aggregate of common stock, preferred stock, debt securities, warrants, and units.
  • At-the-market component: A sales agreement prospectus supplement covers up to $50.0 million of common stock issuable under a sales agreement dated November 9, 2026 with TD Securities (USA) LLC as sales agent.
  • Overlap structure: According to the filing, the $50.0 million ATM amount is included within, not in addition to, the $150.0 million base shelf total.
  • Exchange listing: The filing states the company's common stock is listed on NASDAQ:XGN, with a last reported sale price of $5.81 per share on November 6, 2026.
  • Prior registration expiry: The filing notes that the company's previous Form S-3 (File No. 333-275632) will expire on November 29, 2026, and the company "does not intend to use the Previous Registration Statement prior to expiration."
  • Registrant classification: Exagen is identified in the filing as a non-accelerated filer and a smaller reporting company.

Exagen's $150 Million Shelf Registration and TD Securities ATM Agreement

Exagen Inc., a Delaware corporation headquartered at 1261 Liberty Way, Vista, California, filed a Form S-3 shelf registration statement with the SEC on November 10, 2026. According to the filing, the registration covers potential offerings of common stock, preferred stock, debt securities, warrants, and units, with an aggregate ceiling of $150.0 million. The company's CEO and President is identified as John Aballi, and legal counsel for the filing is listed as Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. of San Diego, California.

Included within the shelf is a sales agreement prospectus supplement tied to an at-the-market equity facility. The filing discloses that Exagen entered into a sales agreement with TD Securities (USA) LLC, dated November 9, 2026, designating TD Securities as sales agent for offerings of up to $50.0 million of common stock. The filing states that this $50.0 million is part of, and not separate from, the $150.0 million total covered by the base prospectus. Sales under the facility may occur "from time to time" after the registration statement becomes effective, according to the filing.

The filing states that specific terms of any securities sold under the base shelf will be set out in future prospectus supplements. The registration was filed on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933. The filing notes that this new registration statement is intended to replace the company's prior Form S-3 (File No. 333-275632), which the filing states will expire on November 29, 2026, and which the company does not plan to use before that expiration.

What Was Disclosed

Exagen filed a Form S-3 shelf registration on November 10, 2026, registering up to $150.0 million in mixed securities, with a $50.0 million common stock ATM facility through TD Securities (USA) LLC under a sales agreement dated November 9, 2026.